Datamonitor's Alcoholic Drinks - Scandinavia Industry Guide is an essential resource for top-level data and analysis covering the Alcoholic Drinks industry in each of the Scandinavian (Denmark, Norway and Sweden) countries. The report includes easily comparable data on market value, segmentation, and five forces analysis, plus full five year market forecasts for each country. It examines future problems, innovations and potential growth areas within the market.

Scope of the Report

* Contains an executive summary market values, and segmentation

* Provides textual analysis of the industry's prospects, competitive landscape and profiles of leading companies

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Compares data from Denmark, Norway and Sweden, alongside individual chapters on each country. .

* Includes a five-year forecast of the industry

Highlights

The Scandinavian alcoholic drinks market had a total market value of $15.9 billion in 2008.

Norway was the fastest growing country with a CAGR of 3.1% over the 2004-2008 period.

Within the alcoholic drinks industry, Sweden is the leading country among the Scandinavian countries, with market revenues of $6.8 billion in 2008.

The alcoholic drinks industry in Sweden is expected to lead the Scandinavian countries with a value of $7.5 billion in 2013.

Why you should buy this report

* Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Market Definition

The alcoholic drinks market consists of beers, ciders & FABs, spirits and wines. The market is valued according to retail selling price (RSP) and includes any applicable taxes.
Any currency conversions used in the creation of this report have been calculated using constant 2008 annual average exchange rates.
For the purposes of this report, Europe comprises Belgium, the Czech Republic, Denmark, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden and the UK.

Report Highlights
Highlights

The Scandinavian alcoholic drinks market had a total market value of $15.9 billion in 2008.

Norway was the fastest growing country with a CAGR of 3.1% over the 2004-2008 period.

Within the alcoholic drinks industry, Sweden is the leading country among the Scandinavian countries, with market revenues of $6.8 billion in 2008.

The alcoholic drinks industry in Sweden is expected to lead the Scandinavian countries with a value of $7.5 billion in 2013.
[Studien Infos ausblenden]

LIST OF TABLES
Table 1: Scandinavia Pharmaceuticals industry, revenue ($ bn) 2004–2013 13
Table 2: Scandinavia Pharmaceuticals industry, revenue ($ bn) 2004–2008(e) 14
Table 3: Scandinavia Pharmaceuticals industry forecast, revenue ($ bn) 2008–2013 15
Table 4: Denmark Pharmaceuticals Market Value: $ billion, 2004-2008 18
Table 5: Denmark Pharmaceuticals Market Segmentation I: % Share, by Value, 2008(e) 19
Table 6: Denmark Pharmaceuticals Market Segmentation II: % Share, by Value, 2008(e) 20
Table 7: Denmark Pharmaceuticals Market Share: % Share, by Value, 2008(e) 21
Table 8: Key Facts: Pfizer Inc 30
Table 9: Key Financials: Pfizer Inc 32
Table 10: Key Facts: Orifarm A/S 33
Table 11: Key Facts: Nycomed International Management GmbH 34
Table 12: Key Financials: Nycomed International Management GmbH 35
Table 13: Key Facts: GlaxoSmithKline Plc 36
Table 14: Key Financials: GlaxoSmithKline Plc 39
Table 15: Denmark Pharmaceuticals Market Value Forecast: $ billion, 2008-2013 40
Table 16: Denmark Size of Population (million) , 2004-2008 41
Table 17: Denmark GDP (Constant 2000 Prices, $ billion), 2004-2008 41
Table 18: Denmark Inflation, 2004-2008 42
Table 19: Denmark Exchange Rate, 2004-2008 42
Table 20: Norway Pharmaceuticals Market Value: $ billion, 2004-2008 44
Table 21: Norway Pharmaceuticals Market Segmentation I: % Share, by Value, 2008(e) 45
Table 22: Norway Pharmaceuticals Market Segmentation II: % Share, by Value, 2008(e) 46
Table 23: Norway Pharmaceuticals Market Share: % Share, by Value, 2008(e) 47
Table 24: Key Facts: Pfizer Inc 56
Table 25: Key Financials: Pfizer Inc 58
Table 26: Key Facts: GlaxoSmithKline Plc 59
Table 27: Key Financials: GlaxoSmithKline Plc 62
Table 28: Key Facts: AstraZeneca PLC 63
Table 29: Key Financials: AstraZeneca PLC 65
Table 30: Norway Pharmaceuticals Market Value Forecast: $ billion, 2008-2013 66
Table 31: Norway Size of Population (million) , 2004-2008 67
Table 32: Norway GDP (Constant 2000 Prices, $ billion), 2004-2008 67
Table 33: Norway Inflation, 2004-2008 68
Table 34: Norway Exchange Rate, 2004-2008 68
Table 35: Sweden Pharmaceuticals Market Value: $ billion, 2004-2008 70
Table 36: Sweden Pharmaceuticals Market Segmentation I: % Share, by Value, 2008(e) 71
Table 37: Sweden Pharmaceuticals Market Segmentation II: % Share, by Value, 2008(e) 72
Table 38: Sweden Pharmaceuticals Market Share: % Share, by Value, 2008(e) 73
Table 39: Key Facts: Pfizer Inc 83
Table 40: Key Financials: Pfizer Inc 85
Table 41: Key Facts: AstraZeneca PLC 86
Table 42: Key Financials: AstraZeneca PLC 88
Table 43: Key Facts: Novartis AG 89
Table 44: Key Financials: Novartis AG 91
Table 45: Sweden Pharmaceuticals Market Value Forecast: $ billion, 2008-2013 92
Table 46: Sweden Size of Population (million) , 2004-2008 93
Table 47: Sweden GDP (Constant 2000 Prices, $ billion), 2004-2008 93
Table 48: Sweden Inflation, 2004-2008 94
Table 49: Sweden Exchange Rate, 2004-2008 94
LIST OF FIGURES
Figure 1: Scandinavia Pharmaceuticals industry, revenue ($ bn) 2004–2013 13
Figure 2: Scandinavia Pharmaceuticals industry, revenue ($ bn) 2004–2008(e) 14
Figure 3: Scandinavia Pharmaceuticals industry forecast, revenue ($ bn) 2008–2013 15
Figure 4: Scandinavia Pharmaceuticals industry, Segmentation (%) 2008 16
Figure 5: Denmark Pharmaceuticals Market Value: $ billion, 2004-2008 18
Figure 6: Denmark Pharmaceuticals Market Segmentation I: % Share, by Value, 2008(e) 19
Figure 7: Denmark Pharmaceuticals Market Segmentation II: % Share, by Value, 2008(e) 20
Figure 8: Denmark Pharmaceuticals Market Share: % Share, by Value, 2008(e) 21
Figure 1: Forces Driving Competition in the Pharmaceuticals Market in Denmark 22
Figure 2: Drivers of Buyer Power in the Pharmaceuticals Market in Denmark 23
Figure 3: Drivers of Supplier Power in the Pharmaceuticals Market in Denmark 24
Figure 4: Factors Influencing the Likelihood of New Entrants in the Pharmaceuticals Market in Denmark 26
Figure 5: Factors Influencing the Threat of Substitutes in the Pharmaceuticals Market in Denmark 28
Figure 6: Drivers of Degree of Rivalry in the Pharmaceuticals Market in Denmark 29
Figure 7: Revenues & Profitability: Pfizer Inc 32
Figure 8: Revenues & Profitability: Nycomed International Management GmbH 35
Figure 9: Revenues & Profitability: GlaxoSmithKline Plc 39
Figure 10: Denmark Pharmaceuticals Market Value Forecast: $ billion, 2008-2013 40
Figure 11: Norway Pharmaceuticals Market Value: $ billion, 2004-2008 44
Figure 12: Norway Pharmaceuticals Market Segmentation I: % Share, by Value, 2008(e) 45
Figure 13: Norway Pharmaceuticals Market Segmentation II: % Share, by Value, 2008(e) 46
Figure 14: Norway Pharmaceuticals Market Share: % Share, by Value, 2008(e) 47
Figure 15: Forces Driving Competition in the Pharmaceuticals Market in Norway 48
Figure 16: Drivers of Buyer Power in the Pharmaceuticals Market in Norway 49
Figure 17: Drivers of Supplier Power in the Pharmaceuticals Market in Norway 50
Figure 18: Factors Influencing the Likelihood of New Entrants in the Pharmaceuticals Market in Norway 52
Figure 19: Factors Influencing the Threat of Substitutes in the Pharmaceuticals Market in Norway 54
Figure 20: Drivers of Degree of Rivalry in the Pharmaceuticals Market in Norway 55
Figure 21: Revenues & Profitability: Pfizer Inc 58
Figure 22: Revenues & Profitability: GlaxoSmithKline Plc 62
Figure 23: Revenues & Profitability: AstraZeneca PLC 65
Figure 24: Norway Pharmaceuticals Market Value Forecast: $ billion, 2008-2013 66
Figure 25: Sweden Pharmaceuticals Market Value: $ billion, 2004-2008 70
Figure 26: Sweden Pharmaceuticals Market Segmentation I: % Share, by Value, 2008(e) 71
Figure 27: Sweden Pharmaceuticals Market Segmentation II: % Share, by Value, 2008(e) 72
Figure 28: Sweden Pharmaceuticals Market Share: % Share, by Value, 2008(e) 73
Figure 29: Forces Driving Competition in the Pharmaceuticals Market in Sweden 74
Figure 30: Drivers of Buyer Power in the Pharmaceuticals Market in Sweden 75
Figure 31: Drivers of Supplier Power in the Pharmaceuticals Market in Sweden 77
Figure 32: Factors Influencing the Likelihood of New Entrants in the Pharmaceuticals Market in Sweden 79
Figure 33: Factors Influencing the Threat of Substitutes in the Pharmaceuticals Market in Sweden 81
Figure 34: Drivers of Degree of Rivalry in the Pharmaceuticals Market in Sweden 82
Figure 35: Revenues & Profitability: Pfizer Inc 85
Figure 36: Revenues & Profitability: AstraZeneca PLC 88
Figure 37: Revenues & Profitability: Novartis AG 91
Figure 38: Sweden Pharmaceuticals Market Value Forecast: $ billion, 2008-2013 92
[Tabellenverzeichnis ausblenden]